04.08.24
Zura Bio Limited, a clinical-stage immunology company, has appointed Robert Lisicki as Chief Executive Officer and Director of the Board at Zura Bio.
Lisicki succeeds Founding CEO, Dr. Someit Sidhu, who will remain involved as a board member, offering continued guidance. Lisicki has extensive experience in the pharmaceutical industry, having held key leadership positions at pharmaceutical organizations of various sizes.
Prior to Arena, Lisicki served as Vice President and General Manager of Inflammation and Cardiovascular at Regeneron Pharmaceuticals. In this dual role, he led both commercial and developmental initiatives. His career also includes senior leadership roles as CEO and Board Member, InCarda Therapeutics; CCO, Daiichi Sankyo, Inc.; and VP, Amgen, with his initial experience in sales and marketing at The Janssen Pharmaceutical Companies of Johnson & Johnson.
"With a successful track record in strategy, commercial operations, and drug development, Robert is well suited to establish Zura Bio as a leading immunology company. On behalf of the board, I would like to welcome Robert,” stated Amit Munshi, Chairman of Zura Bio Board of Directors.
Commenting on the appointment, Lisicki stated, “I’m thrilled to take on this expanded role, and for the opportunity to lead such a talented and experienced team. Zura Bio has made great progress toward what I believe is a bright future, and it is exciting to lead the next chapter of that journey.”
Lisicki succeeds Founding CEO, Dr. Someit Sidhu, who will remain involved as a board member, offering continued guidance. Lisicki has extensive experience in the pharmaceutical industry, having held key leadership positions at pharmaceutical organizations of various sizes.
Experience
Lisicki recently served as President and Chief Operating Officer of Zura Bio and has been serving on the boards of Adiso Therapeutics and Cadrenal Therapeutics, Inc. since October 2023 and July 2023, respectively. He served as the Chief Commercial Officer at Arena Pharmaceuticals from October 2018 to March 2022, where he was accountable for building the company’s global commercial infrastructure and contributed to its mergers and acquisitions activities totaling nearly $8 billion.Prior to Arena, Lisicki served as Vice President and General Manager of Inflammation and Cardiovascular at Regeneron Pharmaceuticals. In this dual role, he led both commercial and developmental initiatives. His career also includes senior leadership roles as CEO and Board Member, InCarda Therapeutics; CCO, Daiichi Sankyo, Inc.; and VP, Amgen, with his initial experience in sales and marketing at The Janssen Pharmaceutical Companies of Johnson & Johnson.
"With a successful track record in strategy, commercial operations, and drug development, Robert is well suited to establish Zura Bio as a leading immunology company. On behalf of the board, I would like to welcome Robert,” stated Amit Munshi, Chairman of Zura Bio Board of Directors.
Commenting on the appointment, Lisicki stated, “I’m thrilled to take on this expanded role, and for the opportunity to lead such a talented and experienced team. Zura Bio has made great progress toward what I believe is a bright future, and it is exciting to lead the next chapter of that journey.”